Bone marrow transplantation for chronic myeloid leukemia

Long-term results

A. Gratwohl, J. Hermans, D. Niederwieser, F. Frassoni, W. Arcese, G. Gahrton, G. Bandini, E. Carreras, J. P. Vernant, A. Bosi, T. De Witte, W. E. Fibbe, F. Zwaan, M. Michallet, T. Ruutu, A. Devergie, A. Iriondo, J. Apperley, J. Reiffers

Research output: Contribution to journalArticle

150 Citations (Scopus)

Abstract

The data on 1480 bone marrow transplants for chronic myeloid leukemia (CML), performed between 1979 and 1990 were reported to the registry of the European Group for Bone Marrow Transplantation (EBMT). Of these, 1082 patients were transplanted in first chronic phase, 88 in subsequent chronic phase, 251 in accelerated phase and 59 during blast crisis. For these four disease stages leukemia-free survival (LFS) at 5 years is 39%, 22%, 22% and 0%, respectively. A more detailed analysis was performed for 947 patients receiving a first transplant in first chronic phase of their disease from an HLA-identical sibling donor. Survival at 8 years is 47%. At 5 years, relapse incidence (RI) is 33% and the transplant-related mortality rate (TRM) is 42%. The major prognostic factors are patient age (LFS, TRM), T cell depletion (LFS, RI), time from diagnosis to transplant (LFS, TRM), white blood cell count (RI) and donor-recipient sex combination (LFS, TRM). This first report on long-term results of a large cohort of transplanted CML patients confirms and extends previous findings. Stage of disease at time of transplant is the most important prognostic factor. Fifty per cent of all patients transplanted for CML in chronic phase can be expected to be alive at 8 years post-transplant, 40% alive and free of the disease. This number increases to > 60% for patients given cyclosporin and methotrexate without T cell depletion as GVHD prophylaxis. However, there is no plateau phase and late relapses and late transplant-related deaths occur in all subcategories. High risk patients can be identified, such as older male patients with a female donor.

Original languageEnglish
Pages (from-to)509-516
Number of pages8
JournalBone Marrow Transplantation
Volume12
Issue number5
Publication statusPublished - 1993

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bone Marrow Transplantation
Transplants
Survival
Leukemia
Recurrence
Mortality
Tissue Donors
Incidence
Leukemia, Myeloid, Chronic Phase
Blast Crisis
T-Cell Leukemia
Leukocyte Count
Methotrexate
Cyclosporine
Registries
Siblings
Bone Marrow
T-Lymphocytes

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Gratwohl, A., Hermans, J., Niederwieser, D., Frassoni, F., Arcese, W., Gahrton, G., ... Reiffers, J. (1993). Bone marrow transplantation for chronic myeloid leukemia: Long-term results. Bone Marrow Transplantation, 12(5), 509-516.

Bone marrow transplantation for chronic myeloid leukemia : Long-term results. / Gratwohl, A.; Hermans, J.; Niederwieser, D.; Frassoni, F.; Arcese, W.; Gahrton, G.; Bandini, G.; Carreras, E.; Vernant, J. P.; Bosi, A.; De Witte, T.; Fibbe, W. E.; Zwaan, F.; Michallet, M.; Ruutu, T.; Devergie, A.; Iriondo, A.; Apperley, J.; Reiffers, J.

In: Bone Marrow Transplantation, Vol. 12, No. 5, 1993, p. 509-516.

Research output: Contribution to journalArticle

Gratwohl, A, Hermans, J, Niederwieser, D, Frassoni, F, Arcese, W, Gahrton, G, Bandini, G, Carreras, E, Vernant, JP, Bosi, A, De Witte, T, Fibbe, WE, Zwaan, F, Michallet, M, Ruutu, T, Devergie, A, Iriondo, A, Apperley, J & Reiffers, J 1993, 'Bone marrow transplantation for chronic myeloid leukemia: Long-term results', Bone Marrow Transplantation, vol. 12, no. 5, pp. 509-516.
Gratwohl A, Hermans J, Niederwieser D, Frassoni F, Arcese W, Gahrton G et al. Bone marrow transplantation for chronic myeloid leukemia: Long-term results. Bone Marrow Transplantation. 1993;12(5):509-516.
Gratwohl, A. ; Hermans, J. ; Niederwieser, D. ; Frassoni, F. ; Arcese, W. ; Gahrton, G. ; Bandini, G. ; Carreras, E. ; Vernant, J. P. ; Bosi, A. ; De Witte, T. ; Fibbe, W. E. ; Zwaan, F. ; Michallet, M. ; Ruutu, T. ; Devergie, A. ; Iriondo, A. ; Apperley, J. ; Reiffers, J. / Bone marrow transplantation for chronic myeloid leukemia : Long-term results. In: Bone Marrow Transplantation. 1993 ; Vol. 12, No. 5. pp. 509-516.
@article{35e548f810b840ccacca3f51e5bc625b,
title = "Bone marrow transplantation for chronic myeloid leukemia: Long-term results",
abstract = "The data on 1480 bone marrow transplants for chronic myeloid leukemia (CML), performed between 1979 and 1990 were reported to the registry of the European Group for Bone Marrow Transplantation (EBMT). Of these, 1082 patients were transplanted in first chronic phase, 88 in subsequent chronic phase, 251 in accelerated phase and 59 during blast crisis. For these four disease stages leukemia-free survival (LFS) at 5 years is 39{\%}, 22{\%}, 22{\%} and 0{\%}, respectively. A more detailed analysis was performed for 947 patients receiving a first transplant in first chronic phase of their disease from an HLA-identical sibling donor. Survival at 8 years is 47{\%}. At 5 years, relapse incidence (RI) is 33{\%} and the transplant-related mortality rate (TRM) is 42{\%}. The major prognostic factors are patient age (LFS, TRM), T cell depletion (LFS, RI), time from diagnosis to transplant (LFS, TRM), white blood cell count (RI) and donor-recipient sex combination (LFS, TRM). This first report on long-term results of a large cohort of transplanted CML patients confirms and extends previous findings. Stage of disease at time of transplant is the most important prognostic factor. Fifty per cent of all patients transplanted for CML in chronic phase can be expected to be alive at 8 years post-transplant, 40{\%} alive and free of the disease. This number increases to > 60{\%} for patients given cyclosporin and methotrexate without T cell depletion as GVHD prophylaxis. However, there is no plateau phase and late relapses and late transplant-related deaths occur in all subcategories. High risk patients can be identified, such as older male patients with a female donor.",
author = "A. Gratwohl and J. Hermans and D. Niederwieser and F. Frassoni and W. Arcese and G. Gahrton and G. Bandini and E. Carreras and Vernant, {J. P.} and A. Bosi and {De Witte}, T. and Fibbe, {W. E.} and F. Zwaan and M. Michallet and T. Ruutu and A. Devergie and A. Iriondo and J. Apperley and J. Reiffers",
year = "1993",
language = "English",
volume = "12",
pages = "509--516",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Bone marrow transplantation for chronic myeloid leukemia

T2 - Long-term results

AU - Gratwohl, A.

AU - Hermans, J.

AU - Niederwieser, D.

AU - Frassoni, F.

AU - Arcese, W.

AU - Gahrton, G.

AU - Bandini, G.

AU - Carreras, E.

AU - Vernant, J. P.

AU - Bosi, A.

AU - De Witte, T.

AU - Fibbe, W. E.

AU - Zwaan, F.

AU - Michallet, M.

AU - Ruutu, T.

AU - Devergie, A.

AU - Iriondo, A.

AU - Apperley, J.

AU - Reiffers, J.

PY - 1993

Y1 - 1993

N2 - The data on 1480 bone marrow transplants for chronic myeloid leukemia (CML), performed between 1979 and 1990 were reported to the registry of the European Group for Bone Marrow Transplantation (EBMT). Of these, 1082 patients were transplanted in first chronic phase, 88 in subsequent chronic phase, 251 in accelerated phase and 59 during blast crisis. For these four disease stages leukemia-free survival (LFS) at 5 years is 39%, 22%, 22% and 0%, respectively. A more detailed analysis was performed for 947 patients receiving a first transplant in first chronic phase of their disease from an HLA-identical sibling donor. Survival at 8 years is 47%. At 5 years, relapse incidence (RI) is 33% and the transplant-related mortality rate (TRM) is 42%. The major prognostic factors are patient age (LFS, TRM), T cell depletion (LFS, RI), time from diagnosis to transplant (LFS, TRM), white blood cell count (RI) and donor-recipient sex combination (LFS, TRM). This first report on long-term results of a large cohort of transplanted CML patients confirms and extends previous findings. Stage of disease at time of transplant is the most important prognostic factor. Fifty per cent of all patients transplanted for CML in chronic phase can be expected to be alive at 8 years post-transplant, 40% alive and free of the disease. This number increases to > 60% for patients given cyclosporin and methotrexate without T cell depletion as GVHD prophylaxis. However, there is no plateau phase and late relapses and late transplant-related deaths occur in all subcategories. High risk patients can be identified, such as older male patients with a female donor.

AB - The data on 1480 bone marrow transplants for chronic myeloid leukemia (CML), performed between 1979 and 1990 were reported to the registry of the European Group for Bone Marrow Transplantation (EBMT). Of these, 1082 patients were transplanted in first chronic phase, 88 in subsequent chronic phase, 251 in accelerated phase and 59 during blast crisis. For these four disease stages leukemia-free survival (LFS) at 5 years is 39%, 22%, 22% and 0%, respectively. A more detailed analysis was performed for 947 patients receiving a first transplant in first chronic phase of their disease from an HLA-identical sibling donor. Survival at 8 years is 47%. At 5 years, relapse incidence (RI) is 33% and the transplant-related mortality rate (TRM) is 42%. The major prognostic factors are patient age (LFS, TRM), T cell depletion (LFS, RI), time from diagnosis to transplant (LFS, TRM), white blood cell count (RI) and donor-recipient sex combination (LFS, TRM). This first report on long-term results of a large cohort of transplanted CML patients confirms and extends previous findings. Stage of disease at time of transplant is the most important prognostic factor. Fifty per cent of all patients transplanted for CML in chronic phase can be expected to be alive at 8 years post-transplant, 40% alive and free of the disease. This number increases to > 60% for patients given cyclosporin and methotrexate without T cell depletion as GVHD prophylaxis. However, there is no plateau phase and late relapses and late transplant-related deaths occur in all subcategories. High risk patients can be identified, such as older male patients with a female donor.

UR - http://www.scopus.com/inward/record.url?scp=0027519484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027519484&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 509

EP - 516

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 5

ER -